QLS32015 + QL2109 + daratumumab

A **combination therapy** consisting of the monoclonal antibodies QLS32015, QL2109, and daratumumab. Daratumumab is a well-characterized monoclonal antibody directed against CD38, highly expressed on the surface of multiple myeloma cells, where it mediates cytotoxicity primarily through apoptosis, antibody-dependent cell-mediated cytotoxicity, and complement-dependent cytotoxicity. QLS32015 and QL2109 are investigational monoclonal antibodies, reportedly being studied in combination with daratumumab. The mechanism of action for QLS32015 and QL2109 is not definitively disclosed in public sources, but as monoclonal antibodies studied in multiple myeloma, they are presumed to have immune-modulatory or cancer cell-directed activities, potentially enhancing anti-tumor efficacy in combination regimens. The primary indication is **multiple myeloma**.